You are viewing an incomplete version of our website. Please click to reload the website as full version.

BCL10 antibody (B-Cell CLL/lymphoma 10)

Details for Product anti-BCL10 Antibody No. ABIN965650, Supplier: Log in to see
Antigen
  • BCL10
  • AI132454
  • BCL-10
  • C81403
  • CARMEN
  • CIPER
  • CLAP
  • ME10
  • cE10
  • c-E10
  • mE10
Alternatives
anti-Human BCL10 antibody for Western Blotting
Reactivity
Human
214
51
39
1
1
Host
120
94
3
Clonality
Monoclonal
Conjugate
This BCL10 antibody is un-conjugated
8
6
6
6
2
2
2
2
1
1
1
1
1
1
1
1
1
1
Application
Immunohistochemistry (IHC), ELISA, Western Blotting (WB)
160
70
69
54
43
37
16
16
12
4
2
1
1
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Showcase your results, aid the scientific community, and receive a full refund.

Contribute a validation

Learn more

Isotype IgG1
Specificity Ni-NTA purified recombinant human BCL-10 expressed in E. Coli strain BL21 (DE3).
Purification Antibodies are purified by protein A affinity chromatography
Alternative Name BCL-10 (BCL10 Antibody Abstract)
Background Bcl-10 is a 31kDa protein containing a caspase recruitment domain (CARD). It plays an important role in apoptosis and activating NF-kappaB. The research suggested that it interacted with other CARD domain containing proteins including CARD9, 10, 11 and 14, which were thought to function as upstream regulators in NF-kappaB signaling. Bcl10 is found to form a complex with MALT1 which encoded by another gene known to be translocated in MALT lymphoma. MALT1 and Bcl-10 are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy.
Gene ID 8915
Pathways TCR Signaling, Fc-epsilon Receptor Signaling Pathway
Application Notes IHC(P): Dilution 1: 100- 1: 500
IHC(F): Dilution 1: 200- 1: 1000
Western blot: Dilution 1: 2000- 1: 5000
ELISA: Propose dilution 1: 10000.
Determining optimal working dilutions by titration test.
Restrictions For Research Use only
Storage -20 °C
Product cited in: Cahill: "Vasoconstrictor responsiveness of portal hypertensive vessels." in: Clinical science (London, England : 1979), Vol. 96, Issue 1, pp. 3-4, 1999 (PubMed).

Background publications Hinoi, Tani, Lucas et al.: "Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon." in: The American journal of pathology, Vol. 159, Issue 6, pp. 2239-48, 2001 (PubMed).

Lucas, Yonezumi, Inohara et al.: "Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway." in: The Journal of biological chemistry, Vol. 276, Issue 22, pp. 19012-9, 2001 (PubMed).

Wang, Guo, Huang et al.: "Card10 is a novel caspase recruitment domain/membrane-associated guanylate kinase family member that interacts with BCL10 and activates NF-kappa B." in: The Journal of biological chemistry, Vol. 276, Issue 24, pp. 21405-9, 2001 (PubMed).

Schillace, Voltz, Sim et al.: "Multiple interactions within the AKAP220 signaling complex contribute to protein phosphatase 1 regulation." in: The Journal of biological chemistry, Vol. 276, Issue 15, pp. 12128-34, 2001 (PubMed).

Willis, Jadayel, Du et al.: "Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types." in: Cell, Vol. 96, Issue 1, pp. 35-45, 1999 (PubMed).

Rudd: "Adaptors and molecular scaffolds in immune cell signaling." in: Cell, Vol. 96, Issue 1, pp. 5-8, 1999 (PubMed).